858979-50-7
858979-50-7 structure
- Name: Sipagladenant
- Chemical Name: Sipagladenant
- CAS Number: 858979-50-7
- Molecular Formula: C20H19N3O4S
- Molecular Weight: 397.45
- Catalog: Signaling Pathways GPCR/G Protein Adenosine Receptor
- Create Date: 2022-09-01 17:26:36
- Modify Date: 2024-04-09 00:44:34
-
Sipagladenant (Compound I) is an orally active adenosine receptor A2A inverse agonist[1]. Sipagladenant can be used in frontal lobe dysfunction research[2].
| Name | Sipagladenant |
|---|
| Description | Sipagladenant (Compound I) is an orally active adenosine receptor A2A inverse agonist[1]. Sipagladenant can be used in frontal lobe dysfunction research[2]. |
|---|---|
| Related Catalog | |
| In Vivo | Sipagladenant (oral administration; 0.3 mg/kg; once) treatment improves cognitive impairment due to a decline in dopamine function in the medial prefrontal cortex[2]. Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve alternation behavior[2]. Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve gait parameters[2]. Animal Model: Medial prefrontal dopaminerjic terminal-lesioned CD(SD) IGS male rat[2] Dosage: 0.3 mg/kg Administration: Oral administration; 0.3 mg/kg; once Result: Showed longer exploration time of the novel object (65.03%) than that of the familiar object (34.97%) (p<0.001). Animal Model: ICR mice with cognitive impairment and/or movement disoder[2] Dosage: 0.1 mg/kg Administration: Oral administration; 0.1 mg/kg; once Result: Showed a significantly high alternation behavior (69.5%) as compared to the vehicle administration group (59.6%) (p<0.01). Animal Model: ICR mice with cognitive impairment and/or movement disoder[2] Dosage: 0.1 mg/kg Administration: Oral administration; 0.1 mg/kg; once Result: Showed a significantly large maximum contact area and gait area of the left hindpaw as compared to the vehicle administration group (p<0.05), tendency of the maximum contact area and gait area of the right forepaw being large (p<0.1). |
| References |
[2]. Horita, Takako. THERAPEUTIC AGENT FOR FRONTAL LOBE DYSFUNCTION, WO2016148308A1. |
| Molecular Formula | C20H19N3O4S |
|---|---|
| Molecular Weight | 397.45 |